This case was reported by a physician via call center representative and described the occurrence of fibromyalgia in a 55-year-old female patient who received RABAVERT. Co-suspect products included RABAVERT, RABAVERT and RABAVERT. On 14th December 2015, the patient received the 1st dose of RABAVERT. On 16 December 2015, the patient received the 2nd dose of RABAVERT. On 21st December 2015, the patient received the 3rd dose of RABAVERT. On 29th December 2015, the patient received the 4th dose of RABAVERT. On 16th December 2015, not applicable after receiving RABAVERT, RABAVERT and RABAVERT, an unknown time after receiving RABAVERT and not applicable after receiving RABAVERT, RABAVERT and RABAVERT, the patient experienced drug dose administration interval too short. On 29th December 2015, the patient experienced drug dose administration interval too long. On an unknown date, the patient experienced fibromyalgia, anxiety attack, neuropathy, tingling of extremity, joint pain, sleeplessness, mobility decreased, neuralgia, hypoesthesia, pain in fingers and burning leg. The patient was treated with ATIVAN. On an unknown date, the outcome of the fibromyalgia, anxiety attack, neuropathy, tingling of extremity, joint pain, sleeplessness, mobility decreased, neuralgia, hypoesthesia, pain in fingers and burning leg were not recovered/not resolved and the outcome of the drug dose administration interval too short and drug dose administration interval too long were unknown. It was unknown if the reporter considered the fibromyalgia, neuropathy, tingling of extremity, joint pain, sleeplessness, mobility decreased, neuralgia, hypoesthesia, pain in fingers and burning leg to be related to RABAVERT, RABAVERT and RABAVERT. It was unknown if the reporter considered the anxiety attack to be related to RABAVERT. Additional details were provided as follows: This case was reported by a physician, who herself was the patient. On 16th December 2015, the patient received 2nd dose of the vaccine, which led to shortening of the vaccination schedule. On 29th December 2015, the patient 4th dose of the vaccine, which led to lengthening of the vaccination schedule. On an unknown date, less than a month after receiving the 4 doses of the vaccine, the patient experienced neuropathy, neuralgia, numbness (hands, feet, head and body), tingling of hands and feet, migratory joint pain and soreness, could not use her right hand, could not sleep, very intense pain in fingers, numbness in scalp and upper back, and back of legs were burning. On 4th January 2016, the patient visited the emergency department and was treated with ATIVAN for diagnosis of anxiety attack. She was discharged on the same day. The patient also underwent MRI of the brain and blood work, both the tests were negative and did not yield any diagnosis. The patient was diagnosed with fibromyalgia. The patient has visited to a number of doctors. The patient did not have any other medical issues apart from the symptoms reported and would like to know how to treat the same. All the reported symptoms were worsening at the time of reporting. At the time of reporting, the batch number and expiry date of the vaccines were unknown.